Ayala Pharmaceuticals Inc (fka ADXS)

[mypekeispooped]

From the 10-Q, regarding ADXS-PSA. I'd say it's positive:

? Median overall survival had not been reached in the combination arm after 13 months of follow-up (95%CI 7.16-NR), and was 7.79 months (95%CI 3.52-11.9) in the monotherapy arm.

? 56.8% of patients on combination therapy and 38.5% of patients on monotherapy did not experience disease progression.

? The percentage of patients with PSA declines from baseline in the combination therapy arm was 40.5%, and 15.4% in the monotherapy arm.

? In all treated patients, an improvement in survival was observed in patients with PSA declines from baseline of 50% or greater vs. those with PSA declines of less than 50%. There were 7 (18%) patients in the combination arm with 50% or greater declines in PSA from baseline, and none in the monotherapy arm.